• A novel controlled-release formulation was developed using QbD principles, achieving sustained drug release over 24 hours.
• The optimized formulation significantly reduced burst release and improved pharmacokinetic profiles, including increased mean residence time.
• In vivo studies in rats showed enhanced bioavailability and reduced peak-trough fluctuations compared to conventional dosage forms.
• The formulation holds promise for improving patient compliance and therapeutic outcomes in chronic disease management.